Progress in Medicinal Chemistry
- 1st Edition, Volume 60 - June 17, 2021
- Imprint: Elsevier
- Editors: Brian Cox, David R. Witty
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 0 5 6 - 8
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 8 9 2 - 2
Progress in Medicinal Chemistry, Volume 60 provides a review of eclectic developments in medicinal chemistry. Each chapter is written by an international board of authors who co… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProgress in Medicinal Chemistry, Volume 60 provides a review of eclectic developments in medicinal chemistry. Each chapter is written by an international board of authors who cover topics including Venoms in Drug Discovery, Designing Protacs as a Drugs, Automated synthesis and enabling tools for Medicinal Chemistry, Use of Molecular Docking Computational Tools in Drug Discovery, and An industrial perspective on co-crystals: screening, identification and development of the less utilized solid form in drug discovery and development.
- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Utilisation of compounds from venoms in drug discovery
- Abstract
- 1: Introduction to venoms and historical perspective
- 2: Approved drugs from venoms
- 3: Composition of venoms: An overview of evolutionary complexity
- 4: Drug like structures within venoms
- 5: Drug like properties of venom components
- 6: Target engagement
- 7: Therapeutic areas and discovery phase leads from venoms
- 8: Strategies for discovering novel actives within venoms
- 9: Utilising SAR with venom peptides
- 10: Future perspective
- Chapter Two: PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
- Abstract
- 1: PROTACs: Heterobifunctional molecules hijacking the UPS
- 2: From concept to practice: Challenges and opportunities in PROTAC development
- 3: Scope of targeted protein degradation
- 4: Current progress in PROTAC translational research
- 5: Emerging approaches in targeted protein degradation
- 6: Summary
- Appendix
- Chapter Three: Automated and enabling technologies for medicinal chemistry
- Abstract
- 1: Introduction
- 2: History of automation in medicinal chemistry
- 3: The current state of automation and established technologies in medicinal chemistry
- 4: Automation gaps and emerging technologies
- 5: Medicinal chemists vs machines: What the future holds
- Chapter Four: Use of molecular docking computational tools in drug discovery
- Abstract
- 1: Introduction
- 2: Molecular docking
- 3: Fragment-based screening
- 4: Protein-protein docking
- 5: Protein-peptide docking
- 6: Nucleic acid docking
- 7: Current challenges
- 8: Looking forward
- Chapter Five: An industrial perspective on co-crystals: Screening, identification and development of the less utilised solid form in drug discovery and development
- Abstract
- 1: Introduction
- 2: What are co-crystals?
- 3: Intellectual property and regulatory perspective on co-crystals
- 4: Generation, characterisation, and development of co-crystals
- 5: Application of co-crystals
- 6: Summary and looking forward
- Edition: 1
- Volume: 60
- Published: June 17, 2021
- Imprint: Elsevier
- No. of pages: 452
- Language: English
- Hardback ISBN: 9780323850568
- eBook ISBN: 9780323858922
BC
Brian Cox
Professor Brian Cox is at University of Sussex, Brighton, UK
Affiliations and expertise
Professor, University of Sussex, Brighton, UKDW
David R. Witty
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.
Affiliations and expertise
WITNET LTD, Cambridge, UKRead Progress in Medicinal Chemistry on ScienceDirect